Why your Ozempic, Wegovy, or Mounjaro claim got denied — and how to appeal

Why this category is hit so hard

GLP-1 medications are expensive (often $900–$1,300 per month at list price), demand has exploded, and many commercial plans wrote exclusions specifically to limit coverage. Most denials we see in this class fall into three patterns.

Pattern 1 — Prior authorization not in place

For diabetes indications (Ozempic, Mounjaro), most plans require prior authorization. Common reasons the prior-auth request fails:

• HbA1c documentation missing from the request.
• Diagnosis code is for prediabetes rather than diabetes.
• Required step therapy (metformin trial) wasn’t documented.
• Prior authorization expired and wasn’t renewed.

The appeal: gather the missing documentation, ask your provider’s office to resubmit prior authorization or attach the documentation to a written appeal that explicitly addresses the insurer’s stated reason.

Pattern 2 — Plan excludes weight-loss medications

For weight-loss indications (Wegovy, Zepbound, Saxenda), many commercial plans contain language like “coverage excludes medications for weight loss.” If your prescription is specifically for weight loss, the appeal is difficult — but possible in some cases:

• If the FDA has approved the specific medication for a covered indication you also have (e.g., Wegovy is FDA-approved for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight), the exclusion may not apply.
• Some plans cover obesity treatment for patients with specific co-morbidities. Read your plan language carefully — the exclusion is often narrower than it first appears.
• Self-funded employer plans sometimes have rider coverage that adds obesity medication coverage; ask HR.

Pattern 3 — Step therapy not completed

Even when GLP-1 medications are covered, plans often require you to try less-expensive alternatives first (step therapy). Common steps include metformin for diabetes or phentermine/topiramate for weight loss. Denials in this category can be appealed by:

• Documenting that prior alternatives were tried and failed (with dates and clinical outcomes).
• Documenting clinical contraindications to the required steps.
• Requesting an exception based on medical urgency or provider judgment.

The evidence package that wins

Across all three patterns, the strongest evidence package includes:

• A treating-provider letter explaining the diagnosis, treatment plan, prior medications tried, and clinical reasoning for the specific GLP-1.
• HbA1c, BMI, or other relevant labs and metrics.
• Documentation of prior medications tried (if step therapy is at issue).
• FDA labeling for the prescribed indication.
• Peer-reviewed support — for example, ADA Standards of Care for diabetes, or AACE Obesity Guidelines.
• Specific plan-language citation (especially important for exclusion denials).

How InsureDefense prepares this appeal

We classify GLP-1 denials in triage and route them to our Premium tier ($499), which includes plan-language citations and peer-reviewed support. Our Provider Evidence Pack ($49) gives your prescriber a template letter and records request to speed up the supporting documentation.

Important caveat: every plan is different, every prescription is different, and we cannot predict any specific outcome. What we can do is structure your appeal so the insurer has every piece of information needed to overturn the denial — and so that, if it doesn’t, you have a strong external-review case.

Upload your denial for a free triage More on Ozempic denials